Multimodal Mesothelioma Treatment Doubles Survival in Mexican Study
| | | |

Multimodal Mesothelioma Treatment Doubles Survival in Mexican Study

Researchers at Mexico’s National Cancer Institute say multimodal mesothelioma treatment with chemotherapy, surgery, and radiation can slow tumor growth and improve survival. Their new study of patients with advanced pleural mesothelioma produced a median survival of nearly two years. That is almost twice as long as average for pleural mesothelioma.  The researchers say the key is a multimodal mesothelioma treatment approach that attacks tumors from three different angles. Chemotherapy Alone is Rarely Enough Chemotherapy is still the main treatment for most patients with pleural mesothelioma. The FDA approved pemetrexed (Alimta) in 2004. Until the recent approval of a combination of Opdivo and Yervoy, Alimta was the only drug for mesothelioma. It is still the main component in mesothelioma chemotherapy. But…

When Pleural and Peritoneal Mesothelioma Occur Together
| | |

When Pleural and Peritoneal Mesothelioma Occur Together

Pleural and peritoneal mesothelioma rarely occur at the same time. But when they do, there is still hope for treatment. That message comes from a new study conducted at Columbia University and published in the Annals of Surgical Oncology. The researchers analyzed cases of patients diagnosed with both pleural and peritoneal mesothelioma at Columbia. They were looking for the factors that impacted their survival and the most effective ways to treat them. Comparing Pleural and Peritoneal Mesothelioma There are two primary types of malignant mesothelioma, the type of cancer most closely associated with asbestos exposure. The most common type is pleural mesothelioma. With this type, the first tumors show up on the membrane that surrounds the lungs (pleura). Chest pain,…